EFFICACY AND SAFETY OF LOCAL TREATMENT OF TRAPEZIUS MYOFASCIAL SYNDROME IN PATIENTS WITH FIBROMYALGIA THROUGH ULTRASOUND-GUIDED INTERFASCIAL BLOCK OF THE TRAPEZIUS MUSCLE

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520345-23-00

Acronym

TRAPEZIUS

Enrollment

Registered

2025-01-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TRAPEZIUS MYOFASCIAL SYNDROME IN FIBROMYALGIA PATIENTS

Brief summary

Visual Analogue Scale (VAS) of regional trapezius pain selected for treatment, at weeks 2, 4 and 12.

Detailed description

Visual Analogue Scale (VAS) of the patient's general pain, Visual Analog Scale (VAS) of patient fatigue, Sensitivity points measured by algometer with a force of 4 kg, WPI and SSS, Sleep assessment: Pittsburg Index (PSQI)., Functional Capacity (FIQ)., Quality of Life (SF-36), Level of anxiety / depression (HAD).

Interventions

DRUGKENACORT 40 mg/ml sospensione iniettabile

DRUGSuero Fisiológico Braun 0

DRUG9% disolvente para uso parenteral Cloruro de sodio

DRUGLidocaína B. Braun 20 mg/ml solución inyectable

DRUGBUPIVACAÍNA PHYSAN 0

DRUG25% SOLUCIÓN INYECTABLE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale (VAS) of regional trapezius pain selected for treatment, at weeks 2, 4 and 12.	—

Secondary

Measure	Time frame
Visual Analogue Scale (VAS) of the patient's general pain, Visual Analog Scale (VAS) of patient fatigue, Sensitivity points measured by algometer with a force of 4 kg, WPI and SSS, Sleep assessment: Pittsburg Index (PSQI)., Functional Capacity (FIQ)., Quality of Life (SF-36), Level of anxiety / depression (HAD).	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026